Drug intelligence / Profile preview

ATH008

Development stage: Unknown
Lead developer: Advancell
Modality: Small Molecules, Transdermal Patches → Device-based Delivery → Drug Delivery Systems, Hydrogel Systems → Drug Delivery Systems
Administration: Topical

Overview

ATH008 is a topical drug candidate developed to prevent and treat dermatological conditions, specifically hand-foot syndrome (palmar-plantar erythrodysesthesia), resulting from chemotherapy. The drug was developed by Advancell and licensed to Helsinn for further development and commercialization. Its primary aim is to enable cancer patients undergoing chemotherapy to complete their treatment schedules by reducing the severity of skin-related side effects, thereby improving quality of life. The exact mechanism of action has not been publicly disclosed, but it is formulated as a cream for local application[1][3][7].

Beyond the preview

Go deeper on ATH008.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ATH008.

Explore the full profile